Abstract 675: B7-H3 targeting ADC GSK5764227 demonstrates broad and varied anti-tumor activity across solid tumor translational models.
Michael Adam(GlaxoSmithKline (United States)), Klaas Bakker(GlaxoSmithKline (United States)), Jenny Laraio(GlaxoSmithKline (United States)), Miriam Doepner(GlaxoSmithKline (United States)), Bjoern-Philipp Kloke(BioNTech (Germany)), Chris Hopson(GlaxoSmithKline (United States)), Prajna Behera(BG Medicine (United States)), Anthony Mazurek(GlaxoSmithKline (United States)), Andrew Gehman(GlaxoSmithKline (United States)), Shoba Shetty(Janssen (United States)), J. Thomas Parsons(GlaxoSmithKline (United States)), Derek Poore(GlaxoSmithKline (United States)), Shannon McKearnan(GlaxoSmithKline (United States)), Ken W. Hance(GlaxoSmithKline (United States)), Ning Sun(GlaxoSmithKline (United States)), Jeremy D. Waight(GlaxoSmithKline (United States))
Cited by 0
Related Papers
Inhibition of Cell Spreading by Expression of the C-Terminal Domain of Focal Adhesion Kinase (FAK) Is Rescued by Coexpression of Src or Catalytically Inactive FAK: a Role for Paxillin Tyrosine Phosphorylation
|Molecular and Cellular Biology|1997|329
Myeloid-derived suppressor cell development is regulated by a STAT/IRF-8 axis
|Journal of Clinical Investigation|2013|319
A T-cell–redirecting bispecific G-protein–coupled receptor class 5 member D x CD3 antibody to treat multiple myeloma
|Blood|2020|167
Activation of Human MutS Homologs by 8-Oxo-guanine DNA Damage
|Journal of Biological Chemistry|2002|165